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Abstract
MicroRNAs are known to control Toll like receptor activation in phagocytes. We have shown that
leukotriene (LT) B4 (LTB4) positively regulates macrophage MyD88 expression by decreasing
suppressor of cytokine signaling-1 (SOCS-1) mRNA stability. Here, we investigated the
possibility that LTB4 control of MyD88 expression involves the generation of microRNAs. Our
data show that LTB4, via its receptor B leukotriene receptor 1 (BLT1) and Gαi signaling,
increased macrophage expression of inflammatory microRNAs, including miR-155, miR-146b,
and miR-125b. LTB4-mediated miR-155 generation was attributable to AP-1 activation.
Furthermore, macrophage transfection with antagomirs against miR-155 and miR-146b prevented
both the LTB4-mediated decrease in SOCS-1 and increase in MyD88. Transfection with miR-155
and miR-146b mimics decreased SOCS-1 levels, increased MyD88 expression, and restored TLR4
responsiveness in both WT and LT-deficient macrophages. Together, our data unveil a heretofore
unrecognized role for the GPCR BLT1 in controlling expression of microRNAs which regulate
MyD88-dependent activation of macrophages.
Introduction
Activation of pattern recognition receptors (PRRs) by either pathogen-associated molecular
pattern molecules (PAMPs) or by endogenous damage-associated molecular pattern
molecules (DAMPs) elicits proinflammatory programs characterized by the production of
inflammatory mediators that are important for the control of microbial infection (1).
However, excessive production of such mediators also results in tissue injury.(2) Among the
PRRs, Toll like receptors (TLRs) are the best studied. TLR family members and the IL-1β
receptor (IL-1βR) share a conserved cytoplasmic Toll–IL-1R (TIR) domain that binds
adaptor proteins, including myeloid differentiation factor 88 (MyD88) (3). MyD88 mediates
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signaling through all of the known TLRs except TLR3. MyD88 is necessary for host defense
against a variety of experimental infections (4, 5), but also promotes development of
atherosclerosis, autoimmune responses, diabetes, colitis, and familial Mediterranean fever
(4, 5). MyD88 directs a variety of signaling programs that culminate in the activation of the
master transcription factor NFκB, leading to the expression of proinflammatory genes (6).
Among the mediators produced by activated macrophages, the 5-lipoxygenase (5-LO)-
derived bioactive lipid leukotriene B4 (LTB4) is conventionally known as a potent
phagocyte chemoattractant, and its role in eliciting acute inflammatory responses as well as
maintaining chronic inflammation is well established (7). We and others have shown that
LTB4 signaling via its cognate receptor B leukotriene receptor 1 (BLT1) through a Gαi-
mediated decrease in cyclic AMP levels enhances phagocytosis and killing of both
opsonized and non-opsonized (8-12) microbes. LTB4 activates NFκB (13) and stimulates
production of cytokines including TNF-α (14), and enhances the production of microbicidal
molecules including ROIs (9), RNIs (15, 16), and antimicrobial peptides. We have also
shown that LTB4 has a permissive role in TLR activation by mediating both basal and
inducible MyD88 expression and NFκB activation in macrophages in vitro and in vivo (13).
Suppressor of cytokine signaling (SOCS-1) is an important inhibitor of JAK2 and
STAT1(17) – a transcription factor for MyD88 (13) – and also impairs TLR activation by
increasing degradation of MyD88-like adaptor (Mal) and IRAKs (18, 19). A key mechanism
of LTB4/BLT1-mediated effects is enhanced degradation of mRNA encoding SOCS-1 (13).
Reducing the SOCS-1 level represents an important step in macrophage activation (19).
SOCS-1 mRNA levels can be controlled both at the levels of transcription and via
microRNA-mediated inhibition. MicroRNAs are small oligonucleotides (~ 22 nt) that bind
complementary sequences in mRNAs, usually resulting in gene silencing via translational
repression or target degradation (20). They are potent regulators of homeostasis and of
pathological conditions. Recent studies have shown that microRNAs are key determinants of
macrophage activation, controlling the expression of a variety of molecules involved in PRR
signaling and NFκB activation (20). There are several reports showing that SOCS-1 is
targeted by different microRNAs, particularly miR-155 but also miR-30b and miR-150
(21-23). The mechanisms underlying expression of microRNAs in macrophages are poorly
understood. It remains to be determined if microRNA expression is modulated by G protein-
coupled receptors. We hypothesized that LTB4/BLT1/Gαi signaling enhances the expression
of microRNAs that will in turn control macrophage TLR activation. Here, we report on the
role of the GPCR BLT1 in the generation of microRNAs involved in SOCS-1 mRNA
degradation, resulting in increased MyD88 expression and TLR-mediated NFκB activation.
We also identified miR-125b as a novel regulator of MyD88 degradation.
Materials and Methods
Animals
8-week-old female 5-LO−/− (B6.129-Alox5tm1Fun; (24)), BLT1−/− (B6.129S4-
Ltb4r1tm1Adl/J; (25)) and strain-matched WT C57BL/6 mice (The Jackson Laboratory) were
maintained according to NIH guidelines for the use of experimental animals with the
approval of the University of Michigan and Indiana University Committees for the Use and
Care of Animals.
Cell harvest
Elicited macrophages were harvested from the peritoneal cavities of mice by lavage with
PBS 4 days after the injection of 2 ml 3% thioglycollate as described previously (11).
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Immunoblotting
Western blots were performed as previously described (11, 13). Protein samples were
resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with
commercially available primary antibodies against MyD88, SOCS-1 (both 1:500; Abcam),
or β-actin (1:10,000; Sigma-Aldrich). Densitometric analysis was performed as described
previously (11, 13).
Measurement of nitrite and TNF-α
Levels of TNF-α were determined by ELISA (R&D Duoset; R&D Systems) as suggested by
the manufacturer. Nitrite, the stable oxidized derivative of NO, was determined using the
Griess reaction (13).
RNA isolation and semiquantitative real-time RT-PCR
Total RNA from cultured cells was isolated using the miRNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. Real-time RT-PCR was performed as
previously described (11, 13).
AP-1 activity assay
WT and 5-LO −/− macrophages were stimulated for 24 h with 100 nM LTB4 in the presence
or absence of the AP-1 inhibitor SR11302 (10 μM), and DNA binding activity in nuclear
extracts (10 μg of protein) was assayed using a transcription factor ELISA for AP-1
(Panomics), according to the manufacturer's instructions.
Targeted miRNA inhibition and overexpression
For inhibition of miR-155, -125b, and -146b, macrophages were transfected using
lipofectamine siRNA max transfection agent with appropriate target antagomirs or anti-miR-
negative control 1 (anti-miR-control). For overexpression, macrophages were transfected
with pre-miR-155, -125b, -146b, or pre-miR-negative control 1 (pre-miR-control).
Transfection reagents, antagomirs, and control miRNAs were purchased from Invitrogen.
Knockdown efficiency and overexpression efficiency was assessed by determining mature
miR-155 and -125b levels in transfected cells. Transfected cells were treated with or without
30 nM microRNA mimic or antagomir for 48 h and, where indicated, treated for indicated
times with LTB4 (100 nM) or LPS (100 ng/ml) before collecting supernatants or preparing
cell lysates for isolation of RNA (RNeasy kit, Qiagen) or proteins.
Luciferase assays
The plasmids containing 3′UTR of murine MyD88 were purchased from Genecopeia, and
those containing the 3’UTR of murine SOCS1 were kindly provided by Christos Tsatsanis,
University of Crete, Heraklion, Greece. Plasmids were packaged in the pEZX-MT01 Vector
(for MyD88) or pMIR-REPORT-luciferase vector (for SOCS-1, Ambion) as described (21).
Constructs were transfected in Raw 264.7 cells in 6-well plates using lipofectamine siRNA
max (Invitrogen). Firefly luciferase reporter gene constructs (0.1 μg per well) were co-
transfected together with 30 nM of microRNA (miR-155, miR-125b and miR-146b or
scrambled-miR control), cells were lysed 24 h after transfection, and luciferase activity was
measured. Each sample was assayed in triplicate.
RNA analysis
Quantitative RT-PCR analyses for miR-125b, miR-146a, miR-155, and RNU6 (used as
normalization control) were performed using TaqMan miRNA assays with reagents,
primers, and probes obtained from Qiagen. In brief, a stem loop primer was used for reverse
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transcription (30 min, 16°C; 30 min, 42°C; 5 min 85°C) followed by qPCR employing
TaqMan probes and primers in a Bio-rad CFX96 Mastercycler. For assessing expression of
SOCS-1, MyD88, b-actin, and the primary microRNAs (pri-miRs) mRNAs, cDNA was
synthesized using a reverse transcription system (miScript II - Qiagem). qPCR was
performed on the CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories) as
described (13). Primers and pri-miRNAs were purchased from Qiagen. Relative expression
was calculated using the comparative threshold cycle (Ct) and expressed relative to control
or WT (ΔΔCt method).
Focused miRNA arrays
To determine the expression of inflammatory microRNAs, WT and 5-LO−/− macrophages
were treated with or without LTB4 for 24 h. RNA was then extracted from the cells using a
Qiagen RNeasy mini kit according to the manufacturer’s instructions. cDNA was
synthesized using the RT2 microRNA First Strand Kit (Qiagen) and applied to PCR focused
immunopathology microRNA array plates (Qiagen). Plates were processed in a BioRad
CFX96 Connect Real-Time PCR System using automated baseline and threshold cycle
detection.
Array normalization and statistical analysis
Normalization and statistical analysis of miRNA expression were conducted using
SABiosciences’ Online PCR Array Data Analysis Web Portal. miRNA expression was
compared between WT and 5-LO−/− cells or between WT cells treated or not with LTB4.
The ΔΔCt method was used to calculate fold change (FC). The endogenous control was
derived from the average FC of four control genes in the PCR arrays, snoRNA251,
snoRNA202, snoRNA142, and U6. The vehicle control group was used as the external
control to normalize each sample. The formula: FC = 2^ [-(mean of ΔCt values of treated
samples - mean of ΔCt values of control samples)] was used to calculate FC for up-regulated
genes, and FC = − 2^ (mean of ΔCt values of treated samples - mean of ΔCt values of
control samples) was used to calculate FC for down-regulated genes. T-tests were used to
calculate significance of differences in miRNA expression between the control and the
treatment groups for each miRNA at each time point; p < 0.01 was considered significant.
miRNAs that displayed threshold cycles (Ct) >35 were excluded from the analysis. Data
were interpreted using SABiosciences’ web-based PCR array data analysis tool (http://
pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
Statistics
Data are presented as mean ± SEM. Comparisons among groups were assessed with
ANOVA followed by Bonferroni analysis; P < 0.05 was considered significant.
Results
LTB4 controls the expression of pro-inflammatory microRNAs in macrophages
We have previously shown that both 5-LO- and BLT1-deficient macrophages manifested a
selective decrease in expression of MyD88 mRNA and protein (13), but not of other
adaptors, and this deficiency was reversed by LTB4 in 5-LO−/− but not in BLT1−/− cells.
Decreased MyD88 was a consequence of higher SOCS-1 expression in LTB4- and BLT1-
deficient animals (13). The increased SOCS-1 mRNA expression in 5-LO−/− macrophages
was associated with an increase in its mRNA stability, while exogenous LTB4 enhanced
degradation of its mRNA (13). Here we sought to determine the molecular mechanism
responsible for LTB4-mediated degradation of SOCS-1 mRNA. We specifically addressed
the capacity of 5-LO metabolites to enhance the expression of microRNAs known to be
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involved in control of expression of both SOCS-1 and of TLRs and/or their adaptors. We
performed a focused microRNA qPCR array (Immunopathogenesis - Qiagen) in WT and 5-
LO−/− macrophages, and found that of 88 microRNAs studied, 22 were downregulated at
least 2.5 fold in LT-deficient cells, including the following microRNAs that amplify TLRs:
Let-7g, miR-155, miR-125b, miR-19a, miR-146a, and miR-146b. 11 microRNAs were
upregulated at least 2.5 fold in 5-LO−/− macrophages and 54 microRNAs were not changed
(Fig. 1A). To confirm these changes identified in the array, we analyzed the expression of
individual microRNAs by qPCR (Fig. 1B). Compared to WT cells, 5-LO−/− macrophages
exhibited lower basal expression of miR-155, miR-125b, and miR-146a b but unchanged
expression of Let-7g.
Since the 5-LO enzyme generates a variety of metabolic products, including both LTB4 and
cysteinyl LTs, we investigated which class of LTs was involved in the regulation of
expression of specific microRNAs. We employed pharmacological means to inhibit 5-LO
activation and to selectively antagonize BLT1 and the cysteinyl LT receptor 1 (cysLT1), and
treated cells with these agents for 24 h prior to microRNA determination. 5-LO inhibition
markedly and significantly decreased the expression of miR-146b and miR-155, and
modestly but significantly decreased that of miR-19a and miR125b (Fig. 1 C). As was also
true for 5-LO−/− cells, no differences were seen in Let-7g expression. BLT1 antagonism
followed the same pattern as observed in 5-LO-inhibited cells (Fig. 1 C). The cysLT1
antagonist MK571 was less effective than BLT1 in decreasing expression of all of the
microRNAs studied with the exception of miR125b. Since endogenous LTB4 appeared to
exhibit a greater effect on microRNA expression than did endogenous cysLTs, we directly
investigated the ability of LTB4 to modulate expression of inflammatory microRNAs known
to target SOCS-1 as well as the resulting consequences with respect to TLR activation.
PCR array analysis of WT macrophages treated with LTB4 for 24 h revealed enhanced
expression of those microRNAs that were downregulated in 5-LO−/− cells, as well as of
additional microRNAs involved in TLR responses (Fig. 2A). We validated the enhancement
by LTB4 of the levels of miR-155 and miR-146b, but not of Let-7g, in both WT and 5-LO−/
− macrophages (Fig. 2B). We also assessed the expression of inflammatory microRNAs in
macrophages from BLT1−/− mice, and found markedly lower expression of miR-155,
miR-146b, and miR-125b than in WT mice (Fig. 2C). Since BLT1 can be coupled to both
Gαi and Gαq in macrophages (8), we sought to determine which G protein accounted for
BLT1 effects on microRNA expression. Basal expression of all the microRNAs studied
except Let-7g was diminished by treatment with the Gαi inhibitor pertussis toxin (PTX)
(Fig. 2D). These data show that Gαi signaling controls basal expression of microRNAs. To
determine whether Gαi actions were also involved in the enhancing effects of LTB4/BLT1
signaling, cells were pretreated with PTX for 18 h, followed by treatment with LTB4 for
another 24 h. PTX treatment substantially decreased LTB4-induced expression of miR-155
and miR-146b, but only partially attenuated LTB4-induced expression of miR-125b,
suggesting a contribution of Gαq signaling in BLT1-mediated expression of this microRNA
(Fig. 2D). Together, these data show a stimulatory effect of the LTB4/BLT1/Gαi axis on the
expression of microRNAs involved in both SOCS-1 expression and TLR activation.
AP-1 mediates LTB4-induced miR-155 expression
As expression of approximately 25% of the microRNAs was lower in LT-deficient cells than
WT cells, we speculated that LTs could be involved in the expression/activation of enzymes
responsible for the generation of microRNAs, such as Dicer and Drosha (26). We observed
an insignificant decrease in Dicer mRNA expression; LTB4 enhanced the expression of
Dicer in 5-LO−/− cells, and no changes in Drosha levels were detected in cells of either
genotype, treated or not with LTB4 (Fig. 3A).
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microRNAs are initially expressed as long primary transcripts termed primary miRNAs (pri-
microRNAs) that undergo sequential processing by Drosha and then Dicer to yield mature
microRNAs (20). In the absence of any change in the expression of enzymes involved in
microRNA biosynthesis, we speculated that LTB4 could be involved in the generation of
pri-microRNAs. Therefore, we measured the amounts of pri-miR-155, pri-miR-146b, pri-
miR-125b, and pri-Let-7g by qPCR. Indeed, expression of all pri-microRNAs other than pri-
Let-7g was lower in both 5-LO/- and BLT1−/− than WT macrophages (Fig. 3B). Lower
expression of these primary microRNAs suggested a role for a LT in the control of the
transcriptional machinery involved in microRNA expression. Activating protein-1 (AP-1) is
a key transcription factor involved in the expression of different primary microRNAs
including miR-155, miR-125b, miR-146a, and miR-146b (27, 28). We tested the ability of
LTB4 to enhance the activation of AP-1 and the subsequent expression of miR-155. Initially,
we performed AP-1 DNA binding assays in WT and 5-LO−/− macrophages incubated with
or without LTB4 for 4 h. LT-deficient cells exhibited lower basal AP-1 activation than WT
macrophages, and LTB4 greatly enhanced AP-1 DNA binding activity in 5-LO−/− cells
(Fig. 3 C). To determine if AP-1 is involved in LTB4-induced miR-155 expression, we
pretreated WT macrophages with the AP-1 inhibitor SR11302 , followed by LTB4 challenge
for 24 h. AP-1 inhibition decreased basal miR-155 levels and attenuated LTB4-enhanced
miR-155 expression (Fig. 3 D). That the AP-1 inhibitor prevents AP-1 DNA binding activity
was confirmed in LTB4-treated cells (Fig. 3C). Together, these findings show that LTB4-
mediated AP-1 activation accounts for the expression of inflammatory microRNAs which
control expression of SOCS-1 and activation of TLR (Fig. 3D).
LTB4-mediated miR-155 and miR-146b expression accounts for increased SOCS-1 mRNA
turnover, MyD88 expression, and TLR4 responsiveness
We previously reported that SOCS-1 acts as a brake on expression of MyD88 by inhibiting
the MyD88 transcription factor STAT-1 (13). SOCS-1 gene silencing allows STAT-1 to be
active and enhances MyD88 expression and improves TLR responsiveness in macrophages
(13). We next sought to determine whether LTB4-enhanced microRNA expression leads to
changes in SOCS-1 and MyD88 levels, and therefore, macrophage function. We transfected
antagomirs known to directly inhibit expression of SOCS-1 (anti-miR-155 and anti-
miR-146b) and MyD88 (anti-miR-125b) into macrophages stimulated or not with LTB4 for
24 h. Our data show that miR-155 inhibition decreased basal MyD88 expression and
prevented LTB4-enhanced MyD88 expression. By contrast, inhibition of miR-125b and
miR-146b enhanced MyD88 above baseline levels, but did not alter levels in the presence of
LTB4. Furthermore, miR-125b increased MyD88 to a greater extent than did miR-146b (Fig.
4 A). As expected (13), LTB4 decreased basal SOCS-1 expression, and miR-155 antagonism
increased both basal and LTB4-induced SOCS-1 expression (Fig. 4 B). However, miR-125b
did not influence SOCS-1 levels, indicating that it instead exerted a direct effect on MyD88
mRNA expression (Fig. 4 B). The miR-146b antagomir enhanced basal SOCS-1 levels and
prevented LTB4 inhibitory effects on SOCS-1 expression (Fig. 4B). These findings were
confirmed by immunoblot (Fig. 4D). As 5-LO−/− cells exhibited lower microRNA
expression, we perform complementary “add-back” experiments, in which miR-155,
miR-146b, and miR-125b precursors (miRNA mimic) were transfected into both WT and 5-
LO-deficient macrophages, and the expression of both MyD88 and SOCS-1 were
determined by qPCR. MyD88 expression was slightly enhanced in WT cells transfected with
miR-155 mimic, and the levels of MyD88 expression were elevated in 5-LO−/− cells
transfected with miR-155 mimic. MyD88 expression was increased by miR-146b mimic and
decreased by miR-125b mimic in both strains studied, again showing that these microRNAs
control MyD88 expression (Fig. 4E). We observed higher SOCS-1 expression in 5-LO−/−
cells than in WT cells as we have previously shown (13), and both miR-155 and miR-146b
transfection decreased SOCS-1 in both WT and 5-LO−/− deficient cells. Transfection of
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miR-125b decreased SOCS-1 levels in 5-LO−/− macrophages but not in WT, indicating a
unique requirement for LTB4 in miR-125b-mediated effects (Fig. 4 E). Together, by
inhibiting SOCS-1 levels with miR-155 and miR-146b mimics, we observed an increase in
MyD88 expression in both WT and 5-LO−/− cells. Next, we determined whether miR-125b,
miR-146b and miR-155 directly target MyD88 and SOCS-1 using Raw 264.7 cells
transfected with either empty vector, 3’ UTR MyD88 or 3’UTR SOCS-1 followed by
addition of the microRNA mimics mentioned above. Our data confirmed that while
miR-125b targets MyD88, miR-146b and miR-155 directly target SOCS-1. The temporal
relationship between microRNAs, SOCS-1 and MyD88 expression was also investigated in
LTB4-stimulated cells. We observed that LTB4 rapidly enhanced miR-155 expression within
1 h, while the decrease in SOCS-1 expression required 4 h. We only observed significant
differences in LTB4-induced MyD88 expression after 24 h, further suggesting that decreased
SOCS-1 accounts for the enhanced MyD88. Together, our data show that LTB4 enhances
MyD88 expression by increasing the expression of microRNAs that directly target SOCS-1.
We next sought to determine if changes in the expression of MyD88 and SOCS-1 influenced
TLR signaling and if increased microRNA expression restored 5-LO−/− macrophage
responsiveness to LPS, which we have previously reported to be impaired (13). WT and 5-
LO−/− macrophages were transfected with mimics of miR-155, miR-125b, or miR-146b for
24 h, followed by LPS stimulation for another 24 h. As expected, 5-LO−/− macrophages
generated less TNF-α and nitrite than WT cells in response to LPS. Transfection of both
miR-155 and miR-146b mimics enhanced LPS-induced TNF-α (Fig. 5A) and NO (Fig. 5B)
production in WT and especially 5-LO−/− cells. In contrast, miR-125b mimic inhibited
LPS-enhanced TNF-α levels exclusively in WT macrophages, which is consistent with the
findings in Fig. 4B.
Discussion
This study highlights a novel regulatory mechanism of microRNA expression induced after
GPCR activation. We have previously shown that BLT1 activation inhibits SOCS-1
expression, leading to enhanced MyD88 expression and consequently increased TLR
activation. Here, we extended these findings by investigating the involvement of BLT1 in
microRNA generation that influences the molecular programs involved in SOCS-1/MyD88
expression. To our knowledge, this is the first demonstration of an essential role for a GPCR
in microRNA generation. More specifically, we found that: 1) LTB4/BLT1/Gαi activation
enhances the expression of inflammatory microRNAs; 2) LTB4/BLT1 activation of AP-1
accounts for the enhanced microRNA generation in macrophages; 3) preventing miR-155
and miR-146b actions abolished LTB4-induced SOCS-1 mRNA degradation; 4) adding back
miR-155 and miR-146b restored MyD88 levels and responsiveness in LT-deficient mice; 5)
miR-125b degrades MyD88 in a manner dependent on LTB4 synthesis.
TLR activation is dictated by fine-tuning events that culminate in important changes in
inflammatory response and host defense (20). Among the “fine-tuners”, microRNAs are
known to inhibit the expression of many key components of the TLR signaling program,
including MyD88 (29, 30), IRAKs (31-33) and TRAF-6 (33-35). microRNAs can be
produced constitutively or be upregulated by a variety of inflammatory stimuli, including
LPS (21, 36-38), Poly(I:C) (37, 38) and TNF-α (36). However, whether GPCRs also
participate in the generation of microRNAs is unknown. We have shown that the other
major class of 5-LO metabolite, the CysLTs, did not exert effects on most microRNAs,
excluding miR-125b, emphasizing the specific and nonredundant role of LTB4 in regulating
microRNAs that control SOCS-1 expression in macrophages. Also striking was the fact that
the upregulatory influence on microRNA expression was observed not only following the
addition of exogenous LTB4, but also under basal conditions, in which levels of constitutive
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endogenous LTB4 generation would be expected to be quite low. Basal release of LTB4 by
elicited peritoneal macrophages from WT animals over 90 min was approximately 100 pg/
ml, which is equivalent to 0.5 nM (13). This concentration is indeed sufficient to activate
BLT1, since we have shown that LTB4 amplifies AM antimicrobial functions at
concentrations as low as 0.01 nM (8). These findings support the conclusion that LTB4 is a
homeostatic regulator of microRNA expression that controls numerous aspects of
macrophage biology.
We also identified Gαi-independent microRNA expression, such as that of miR-125b and
miR19a (not shown). The relative role of other G proteins, such as Gαq and Gαs, in
modulating expression of microRNAs that regulate macrophage biology is an active area of
research in our laboratory.
The fact that LT deficiency decreased the expression of a myriad of microRNAs suggested
the possibility that LTs enhance the expression/activity of the enzymes involved in
microRNA biogenesis, such as Dicer and Drosha (20, 39). Although we did not observe any
effect of LTs on the expression of these enzymes, we cannot exclude possible actions of
LTB4 on Dicer or Drosha activation. It remains to be determined whether GPCRs also
influence the expression or activation of enzymes involved in the microRNA machinery. A
variety of transcription factors have been implicated in microRNA generation, such as
NFκB (40), Egr (41, 42) and AP-1 (27, 43-46). We further investigated whether LTB4/
BLT1 could enhance the generation of microRNAs by controlling activation of AP-1 since
this transcription factor is responsible for the expression of miR-155 and also miR-146b (27,
28). AP-1 regulates gene expression in cells activated by a myriad of stimuli, including
proinflammatory cytokines, TLR ligands, growth factors, and stress (45). Upon cell
activation, regulation of gene expression by AP-1 is dependent mainly on activation of MAP
kinases, including ERK1/2 and p38 (45). We and others have shown that LTB4 activates
ERK1/2 and p38 in macrophages (47, 48). However, whether LTB4 enhances AP-1
activation is controversial. Stankova, et. al., have shown that LTB4 enhances expression and
DNA binding activity of the AP-1 member c-fos (49), while Brach, et al showed that AP-1
is not affected by LTB4 in stimulated human monocytes (50). Here, we showed that LTB4
activates AP-1 to enhance miR-155 expression. AP-1 binding to the BIC promoter of these
microRNAs has been previously reported in both human and mouse cells (27, 44, 51, 52).
Furthermore, McCoy et. al., (53) have shown that Ets3 activation inhibits miR-155
expression. Whether LTB4 enhances miR-155 expression by activating transcription factors
other than AP-1, such as NFκB, or by inhibiting Ets3 actions, remains to be determined.
We further investigated whether changes in microRNA levels account for changes in the
expression of SOCS-1 and MyD88 in macrophages from LT-deficient mice, and found that
miR-155 and miR-146b decrease SOCS-1 levels and miR-125b inhibits MyD88 only. We
recognize that these microRNAs could be modulating the expression of SOCS-1 and
MyD88 indirectly. Therefore, we employed different complementary approaches such as
antagomir treatment of LTB4-treated cells and 3’-UTR luciferase assay to further confirm
our findings. Our findings confirm that miR-155 inhibits SOCS-1 expression and newly
identify that miR-125b targets MyD88 and miR-146b targets SOCS-1. A caveat of our
studies is that we cannot exclude a potential indirect effect of the microRNA mimics in the
degradation of SOCS-1 and MyD88 3’UTR constructs in RAW 264.7 macrophages, since
we did not transfect macrophages with the mutants lacking the 3’UTR microRNA binding
sites. The temporal relationship in the expression of these molecules is consistent with a
causal role for miR-155 in the degradation of SOCS-1 and MyD88, as the increase in
miR-155 expression (noted 1 h after LTB4 treatment) preceded the decrease in SOCS-1
levels (noted after 4 h), which in turn preceded the increase in MyD88 levels (noted after 24
h). Although we did not measure the temporal expression of the other microRNAs, the
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microRNA mimic and antagomir data supporting the roles of miR-146b in control of
SOCS-1 and of miR-125b in the control of MyD88 strongly imply that these microRNAs
too would be expected to precede changes in levels of their target genes. Furthermore, we
cannot definitively exclude the possibility that the microRNAs studied here might target
other genes that also influence TLR activation. The fact that miR-125b does not further
inhibit MyD88 expression and TNF-α levels in 5-LO−/− cells is intriguing, and the
molecular programs involved in these events will be studied in the future. Another intriguing
fact is that miR-125b suppresses LTB4-induced SOCS1 mRNA without affecting its UTR.
We speculate that the effect of miR-125b on SOCS-1 is indirect, by targeting either
transcription factors involved in SOCS-1 mRNA or by changing the levels of other
microRNAs that further degrade SOCS-1 in LTB4-treated cells.
In summary, our findings show that LTB4, via its cognate receptor BLT1 and Gαi protein
activation, enhances the expression of microRNAs known to degrade SOCS-1 levels and
thereby enhances MyD88 protein expression and TLR responsiveness. We also showed for
the first time that miR-125b targets MyD88 directly. These data demonstrate that GPCRs
amplify innate immune and inflammatory responses by modulating the expression of
important microRNAs that further control macrophage activation. It will be of interest to
dissect the interplay between GPCR signaling and microRNAs in in vivo host defense and
inflammatory responses. Our findings have direct translational importance, as unveiling the
LTB4/BLT1/microRNA axis to control TIR-dependent macrophage activation would be
expected to attenuate excessive NFκB activation which contributes to tissue injury (4, 6) or
of unchecked IL-1βR activation in autoinflammatory conditions (54). Moreover, states of
immunosuppression might be overcome by administration of exogenous LTB4 plus
microRNA mimics, such as miR-155 and miR-146b.
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Figure 1. Role of 5-LO metabolites in the expression of pro-inflammatory microRNAs in
macrophages
(A) Thioglycollate-elicited macrophages from WT and 5-LO−/− mice were harvested, and
total RNA was isolated. MicroRNAs were isolated and subjected to miScript cDNA
synthesis and to real time PCR array as described in Materials and Methods. Data are
representative of 5 individual experiments. (B) Detection of individual microRNAs in WT
and 5-LO−/− macrophages. Detection of miR-155, Let-7g and miR-146b was performed as
described in Materials and Methods. (C) WT MΦs treated with the 5-LO inhibitor AA-861,
the BLT1 antagonist U7532 and the cysLT1 antagonist MK571 (all at 1 μM) for 24 h,
followed by determination of the indicated microRNAs. Data are mean ± SEM from 3
individual experiments, each performed in triplicate. *P < 0.05 versus untreated WT; #P <
0.05 versus WT control or LTB4 alone.
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Figure 2. LTB4/BLT1 enhances expression of microRNAs in macrophages
(A) WT macrophages were stimulated or not with 100 nM LTB4 for 24 h and total RNA was
isolated. microRNAs were isolated and subjected to miScript cDNA synthesis. A real time
PCR array was performed as described in Materials and Methods. Data are representative of
5 individual experiments. (B) Detection of individual microRNAs in WT and 5-LO−/−
macrophages stimulated with 100 nM LTB4 for 24 h and in unstimulated WT controls.
Detection of miR-155, Let-7g and miR-146b was performed as described in Materials and
Methods. Data represent 3-5 independent experiments performed in triplicate. (C)
microRNAs were isolated from WT and BLT1−/− macrophages, and the expression of
Let-7g, miR-155, miR-146b, miR-19a, and miR-125b was determined by real time RT-PCR.
Dashed line shows the level of microRNAs detected in WT macrophages normalized to
100%. Data represent 3-5 independent experiments performed in triplicate. (D) WT
macrophages were pretreated for 24 hours with or without the Gαi inhibitor PTX (600 ng/
ml), followed by 30 minutes of treatment with or without LTB4. The expression of the
indicated microRNAs was detected as in B. In B-D data are mean ± SEM from 3 individual
experiments, each performed in triplicate. *P < 0.05 versus untreated WT; #P < 0.05 versus
WT control or LTB4 alone.
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Figure 3. LTB4/BLT1-induced AP-1 activation is required for miR-155 expression
(A) Thioglycollate-elicited macrophages from WT and 5-LO−/− mice were treated or not
with 100 nM LTB4 for 24 h, and the expression of Dicer or Drosha were determined by
qPCR. (B) Macrophages from WT and 5-LO−/− mice were stimulated as in A and the
expression of indicated pri-microRNAs were determined by qPCR. (C) Macrophages from
WT and 5-LO−/− mice were stimulated as in A or pretreated with the AP-1 inhibitor
SR11302 for 30 min before stimulation with LTB4 and nuclear AP-1 activity was
determined as described in Materials and Methods. (D) WT macrophages were incubated
with the AP-1 inhibitor SR11302 for 30 min before stimulation with LTB4 for 24 h.
miR-155 expression was determined as described in Materials and Methods. Data represent
mean ± SEM from 3-5 individual experiments, each performed in triplicate. *P < 0.05
versus unstimulated WT; #P < 0.05 versus stimulated WT.
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Figure 4. miR-155 and miR-146b levels control LTB4-mediated SOCS-1 inhibition and enhanced
MyD88 levels
(A) Thioglycollate-elicited macrophages from WT were transfected with 30 nM of miR-155,
miR-146b, or miR-125b antagomir for 24 h, then stimulated with 100 nM LTB4 for another
24, followed by determination of (A) MyD88 or (B) SOCS-1 mRNA levels or protein (C).
(D and E) WT and 5-LO−/− macrophages were transfected with 30 nM of the mimics
miR-155, miR-146b, or miR-125b for 48 h followed by determination of MyD88 (D) and
SOCS-1 (E) mRNA levels as described in Materials and Methods. Inset: The predicted
miR-146b and miR-125b binding sites located in the 3′-UTR of SOCS-1 and MyD88,
respectively. The sequence alignment of miR-146b/SOCS-1 and miR-125b/MyD88 is
shown, and perfect matches are indicated by a line. (F) Raw264.7 macrophages were
transfected with a luciferase construct containing the 3′ UTR of SOCS1, 3’ UTR of MyD88
and empty vector expressing luciferase reporter plasmid followed by the microRNA mimics
miR-155, miR-146b and miR-125b for 24 h and the luciferase activity was determined as
described in the Material and Methods. (G) WT macrophages were stimulated with 100 nM
LTB4 for different time points and the expression of miR-155, SOCS-1 and MyD88 were
determined by qPCR. Data represent mean ± SEM from at least 3 individual experiments,
each performed in triplicate. *P < 0.05 versus unstimulated WT; #P < 0.05 versus stimulated
WT.
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Fig. 5. miR-155 and miR-146b mimic overcome LPS responsiveness in LT-deficient
macrophages
WT and 5-LO−/− macrophages were transfected with 30 nM of the mimics miR-155,
miR-146b, or miR-125b for 48 h, stimulated with LPS for 24 h, and TNF-α (A) and NO (B)
levels were detected by ELISA and Griess reaction, respectively. Data represent mean ±
SEM from 3 individual experiments, each performed in triplicate. *P < 0.05 versus
unstimulated WT; #P < 0.05 versus stimulated WT.
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